Latest Capital Raises News

Page 213 of 548
Elixinol Wellness Limited reported a 12.8% increase in revenue to $7.64 million for the half-year ended June 2025, yet its net loss widened by 12.2% to $3.09 million, reflecting higher marketing and restructuring expenses following recent acquisitions.
Victor Sage
Victor Sage
29 Aug 2025
DTI Group Ltd reported an 11% revenue increase and secured a $4 million Adelaide Metro contract, alongside a $2.69 million capital raise to fuel growth. The company also deepened global partnerships and enhanced its technology platform during FY25.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Papyrus Australia Ltd reported a sharp increase in losses for FY2025, driven by impairment of its Egyptian investments, while securing new funding and advancing commercialization of its banana fibre technology.
Victor Sage
Victor Sage
29 Aug 2025
Adherium Limited reported a $12.68 million net loss for FY2025 as it pivots towards commercialising its smart inhaler technology in the US, supported by a $4.49 million capital raise.
Ada Torres
Ada Torres
29 Aug 2025
Nanollose Limited reported a $1.43 million loss for FY2025 while progressing pilot production of innovative biomaterials and strengthening its balance sheet with a $2.1 million capital raise. The company appointed a new CEO to drive commercialisation efforts in FY2026.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Macarthur Minerals Limited reported a successful capital raise and key strategic partnerships at its 2025 AGM, positioning itself for future growth in iron ore production.
Maxwell Dee
Maxwell Dee
29 Aug 2025
DigitalX Limited posted a larger loss for FY25 despite an 18% revenue increase, driven by digital asset appreciation and a bold Bitcoin accumulation strategy.
Claire Turing
Claire Turing
29 Aug 2025
Bridge SaaS Limited reported a remarkable 524.6% revenue jump to $7.47 million for FY25, driven by its acquisition of Brightside Disability Support & Respite. Despite this growth, the company narrowed its loss to $1.13 million but remains unprofitable.
Sophie Babbage
Sophie Babbage
29 Aug 2025
Paradigm Biopharmaceuticals marked FY25 with the launch of its global Phase 3 trial for its osteoarthritis drug iPPS, backed by strong FDA protocol approval and a $41 million funding facility. The company also broadened its pipeline with the acquisition of Pentacoxib™, targeting early-stage OA.
Ada Torres
Ada Torres
29 Aug 2025
KneoMedia has narrowed its FY25 net loss by 38%, driven by cost controls and a strategic shift to its scalable KneoScience EdTech platform. The company also secured a $700,000 order for FY26, signaling growing traction in the US education market.
Victor Sage
Victor Sage
29 Aug 2025
First Graphene Limited reported a 13% reduction in net loss for FY25 alongside steady revenue and expanding commercial demand for its PureGRAPH products.
Maxwell Dee
Maxwell Dee
29 Aug 2025
Powerhouse Ventures Limited reported a striking 348.8% jump in profit after tax to $1.82 million for FY25, driven by strategic acquisitions and a robust investment portfolio. The company’s first operating cash profit and growth in net tangible assets signal a turning point in its transformation.
Claire Turing
Claire Turing
29 Aug 2025